Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ETHYLENEDIAMINE: 45 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
45
Total FAERS Reports
14 (31.1%)
Deaths Reported
35
Hospitalizations
45
As Primary/Secondary Suspect
15
Life-Threatening
15
Disabilities

First Report: 20080101 · Latest Report: 20250225

What Are the Most Common ETHYLENEDIAMINE Side Effects?

#1 Most Reported
Drug hypersensitivity
37 reports (82.2%)
#2 Most Reported
Drug intolerance
32 reports (71.1%)
#3 Most Reported
Drug ineffective
32 reports (71.1%)

All ETHYLENEDIAMINE Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Drug hypersensitivity 37 82.2% 11 31
Drug ineffective 32 71.1% 11 32
Drug intolerance 32 71.1% 11 32
Condition aggravated 31 68.9% 10 30
Hepatotoxicity 31 68.9% 11 31
Musculoskeletal stiffness 31 68.9% 11 31
Pain in extremity 31 68.9% 11 31
Arthralgia 30 66.7% 9 30
Infection 30 66.7% 9 30
Joint swelling 30 66.7% 11 30
Neoplasm malignant 30 66.7% 10 30
Treatment failure 30 66.7% 9 30
Arthropathy 29 64.4% 9 29
Pulmonary toxicity 29 64.4% 8 29
Therapeutic product effect incomplete 29 64.4% 9 29
Gastrointestinal toxicity 28 62.2% 8 28
Joint injury 28 62.2% 8 28
Musculoskeletal pain 28 62.2% 9 28
Therapy non-responder 28 62.2% 8 28
Joint stiffness 27 60.0% 8 27

Who Reports ETHYLENEDIAMINE Side Effects? Age & Gender Data

Gender: 97.1% female, 2.9% male. Average age: 45.0 years. Most reports from: CA. View detailed demographics →

Is ETHYLENEDIAMINE Getting Safer? Reports by Year

YearReportsDeathsHosp.
2008 8 5 8
2019 1 0 0
2020 1 0 0
2025 1 0 0

View full timeline →

What Is ETHYLENEDIAMINE Used For?

IndicationReports
Product used for unknown indication 35

Official FDA Label for ETHYLENEDIAMINE

Official prescribing information from the FDA-approved drug label.